Hypersence Data Room
Hypersence is pioneering the future of enhanced cognitive performance with MemorySPEX™, our patent-pending NeuroWellness™ wearable designed to improve cognitive performance—as easy as putting on a pair of glasses.
MemorySPEX is currently onboarding with Walgreens, creating a potential pathway to more than 10,000 stores nationwide and large-scale consumer distribution.
Based on our financial projections, we only need placement in approximately 2,000 stores to support a forecasted $3 billion exit valuation, excluding any revenues related to Alzheimer's disease.
Winner of Stanford University's Chairman's Choice Award, MemorySPEX™ combines neuroscience, wearable technology, and artificial intelligence to address one of the fastest-growing opportunities in brain health and consumer wellness.
Our strategy is to first compete in the $14 billion brain health market before pursuing a predicate device pathway for the treatment of Alzheimer's disease.
We are currently raising a $3 million seed round to support manufacturing, commercialization, and growth as we work to help millions achieve their dreams of a better life through enhanced cognitive performance.
Interested in learning more about the MemorySPEX investment opportunity?
Review our Investor Video, Pitch Deck, Executive Summary, Financial Model, and supporting due diligence materials in the Data Room. If you believe MemorySPEX may be a fit for your portfolio, schedule a meeting to discuss the opportunity directly with founder and CEO Kim Lavine.
Why are physicians investing in MemorySPEX™?
Why is Walgreens onboarding MemorySPEX™?
And why do we believe MemorySPEX™ has the potential to define an entirely new NeuroWellness™ category?
Watch this brief presentation to learn why we believe MemorySPEX™ represents one of the most compelling opportunities in brain health, consumer wellness, and Alzheimer's treatment.
The opportunity is enormous. The need is real. And the timing has never been better.
Walgreens onboarding with a pathway to more than 10,000 stores nationwide
Projected $3 billion exit valuation based solely on our consumer wellness strategy
Alzheimer’s treatment as a predicate device
Patent-pending technology
Stanford’s Chairman’s Choice Award Winner
Decades of supporting scientific research
$14 billion U.S. brain health market
Safe, non-invasive General Wellness classification
Experienced leadership team with a history of commercializing innovative products
DUE DILIGENCE MATERIALS
(email me at kim@hypersence.com for financials in Excel format.)
FDA General Wellness Policy for Low Risk Devices
The information contained herein is not an offer to sell, or a solicitation of an offer to buy, any securities and is qualified in its entirety by the more complete information, including risks of investment, provided by Hypersence, in its sole discretion, to certain qualified investors who meet certain investor criteria. There is no assurance that we will achieve any of our investment objectives, and investment results may vary substantially over time.